ResQ201A trial: what clinicians have said so far
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- NCT06745908 ↗
- Recruiting
- ImmunityBio, Inc.
- Focused size, estimated: 1–150 verified statements once built
Discussed at: European Lung Cancer Congress 2026, ESMO Congress 2026
We haven't built an HCP commentary report on ResQ201A (nogapendekin alfa inbakicept (N-803) plus tislelizumab; nogapendekin alfa inbakicept (N-803) in immune checkpoint inhibitor-resistant stage IV NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ResQ201A so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 6 posts on X, typically up to 26 once built |
The trial
ClinicalTrials.gov- Official title
- Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- NSCLC Stage IV
- Interventions
- N-803; Tislelizumab; Docetaxel; Prior failed checkpoint inhibitor
- Arms
- Cohort A: Experimental Arm · Experimental
- Cohort A: Control Arm · Active comparator
- Cohort B: Experimental Arm · Experimental
- Cohort B: Control Arm · Active comparator
- Enrollment
- 507 (estimated)
- Primary outcomes
- Compare Overall Survival between the experimental and control arms
- Sponsor
- ImmunityBio, Inc.
- Start
- Oct 1, 2025
- Primary completion
- Sep 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06745908 · updated Nov 2, 2026